Cargando…

Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis

BACKGROUND & OBJECTIVES: Patients with autoimmune rheumatic diseases may be at an increased risk of infection due to disease and use of disease-modifying antirheumatic drug (DMARD) therapy. The present study was done to evaluate the immune response to influenza vaccination in patients with rheum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Vikramraj K., Bhashini, Nandhini, Balajee, L. Karthik, Sistla, Sujatha, Parija, Subhash Chandra, Negi, Vir Singh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663159/ https://www.ncbi.nlm.nih.gov/pubmed/28862177 http://dx.doi.org/10.4103/ijmr.IJMR_920_15

Ejemplares similares

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Pericardial effusion – an unusual manifestation of salmonellosis: a case report
por: Sahu, Manisa, et al.
Publicado: (2008)

Risk factors for intestinal colonization with vancomycin resistant enterococci’ A prospective study in a level III pediatric intensive care unit
por: Amberpet, Rajesh, et al.
Publicado: (2018)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
por: Strand, Vibeke, et al.
Publicado: (2015)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus: A preliminary report from south India
por: Amberpet, Rajesh, et al.
Publicado: (2019)

Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
por: Benucci, Maurizio, et al.
Publicado: (2011)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
por: Kelly, Ayano, et al.
Publicado: (2018)

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
por: Jung, Gyu-Un, et al.
Publicado: (2018)

An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2018)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
por: van Heuckelum, Milou, et al.
Publicado: (2019)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
por: Jin, Yinzhu, et al.
Publicado: (2017)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
por: Sullivan, Emma, et al.
Publicado: (2020)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
por: Jin, Yinzhu, et al.
Publicado: (2023)

Arcanobacterium haemolyticum associated with pyothorax: case report
por: Parija, Subhash Chandra, et al.
Publicado: (2005)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Epidemiology and phylogenetic analysis of respiratory viruses from 2012 to 2015 – A sentinel surveillance report from union territory of Puducherry, India
por: Palani, Nandhini, et al.
Publicado: (2020)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
por: Mousavi, Maryam, et al.
Publicado: (2019)

Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Costello, Ruth E, et al.
Publicado: (2020)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
por: Ozen, Gulsen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v8a9q7shm4o1jm06rqop2oa8i6